Synthesis and Biological Evaluation of Novel Anthranilamide Derivatives as Anticancer Agents
News Oct 23, 2013
A new series of anthranilamide derivatives were synthesized and evaluated for their antiproliferative activities against human colon carcinoma cell lines (HCT 116) and human breast adenocarcinoma cell lines (MDA-MB-231) in vitro. The bioassay results indicated that compounds 7a-7d, 11a, and 11b with flexible linkers showed promising antiproliferative activity against both cell lines. Among the compounds synthesized, 7c showed the most significant antiproliferative activity. Flow cytometric analysis indicated that 7c inhibited HCT 116 and MDA-MB-231 cell growth by inducing apoptosis in a dose-dependent manner and suppressed HCT 116 cell proliferation by G1 and S phase arrest. Compound 7c may serve as a lead candidate in the development of novel anticancer agents.
This article was published online in Drug Discoveries and Therapeutics and is free to access.
The 2018 IUPAC-ThalesNano prize has been awarded to Professor C. Oliver Kappe. Prof. Kappe has made an extremely high impact on the development of flow chemistry and contributed to the penetration of continuous processes worldwide from the academia to fine-chemical and pharma industry.READ MORE